COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,678 Articles (22,913 medRxiv, 8,765 bioRxiv)

Most recent first Previous |  Page 2673: Articles 26721-26730  | Next

Effectiveness of stay-in-place-orders during COVID-19 pandemic: Evidence from US border counties.
Devaraj, S., Patel, P. C.
10.1101/2020.06.08.20125419 — Posted: 2020-06-09
Examine the impact of weather and ambient air pollutant parameters on daily case of COVID-19 in India.
Das, K., Chatterjee, N. D.
10.1101/2020.06.08.20125401 — Posted: 2020-06-09
Intimate Partner Violence Victimization and Perpetration among U.S. Adults during COVID-19: A Brief Report
Davis, M., Gilbar, O., Padilla-Medina, D.
10.1101/2020.06.08.20125914 — Posted: 2020-06-09
Quantifying hospital flows and occupancy due to COVID-19 outbreak in France. Was French lockdown effective?
Ternant, D.
10.1101/2020.06.08.20125765 — Posted: 2020-06-09
Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples
Herzog, S., De Bie, J., Abrams, S., Wouters, I., Ekinci, E., Patteet, L., Coppens, A., De Spiegeleer, S., Beutels, P., Van Damme, P., Hens, N., Theeten, H.
10.1101/2020.06.08.20125179 — Posted: 2020-06-09 Discussion: Onsite
Benchmarking Deep Learning Models and Automated Model Design for COVID-19 Detection with Chest CT Scans
He, X., Wang, S., Shi, S., Chu, X., Tang, J., Liu, X., Yan, C., Zhang, J., Ding, G.
10.1101/2020.06.08.20125963 — Posted: 2020-06-09
Impact of Timing of and Adherence to Social Distancing Measures on COVID-19 Burden in the US: A Simulation Modeling Approach
Alagoz, O., Sethi, A., Patterson, B., Churpek, M., Safdar, N.
10.1101/2020.06.07.20124859 — Posted: 2020-06-09 Discussion: Onsite
Principles and Practice of SARS-CoV-2 Decontamination of N95 Masks with UV-C
Huber, T., Goldman, O., Epstein, A. E., Stella, G., Sakmar, T. P.
10.1101/2020.06.08.20125062 — Posted: 2020-06-09 Discussion: Onsite
Temporal evolution of COVID-19 in the states of India using SIQR Model
TIWARI, A.
10.1101/2020.06.08.20125658 — Posted: 2020-06-09
A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis
Laing, A. G., Lorenc, A., Del Molino Del Barrio, I., Das, A., Fish, M., Monin, L., Munoz-Ruiz, M., Mckenzie, D., Hayday, T., Francos Quijorna, I., Kamdar, S., Joseph, M., Davies, D., Davis, R., Jennings, A., Zlatareva, I., Vantourout, P., Wu, Y., Sofra, V., Cano, F., Greco, M., Theodoridis, E., Freedman, J., Gee, S., Nuo En, Chan, J., Ryan, S., Bugallo Blanco, E., Peterson, P., Kisand, K., Haljasmagi, L., Martinez, L., Merrick, B., Bisnauthsing, K., Brooks, K., Ibrahim, M., Mason, J., Lopez Gomez, F., Babalola, K., Abdul- Jawad, S., Cason, J., Mant, C., Doores, K., Seow, J., Graham, C., di Rosa, F., Edgeworth, J., Shankar Hari, M., Hayday, A.
10.1101/2020.06.08.20125112 — Posted: 2020-06-09 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).